ZS Pharma: AstraZeneca aims for ZS Pharma kidney drug approvals in H1 2018
AstraZeneca says its hyperkalaemia candidate ZS-9 is back on track for approval after manufacturing issues at its Texas facility resulted in regulatory delays.
Read full article »
CEO
ZS Pharma develops and commercializes non-absorbed drugs to treat renal, cardiovascular, liver and metabolic diseases.
Read more